ANALYSIS OF AGOMELATINE TREATMENT WITH DEPRESSIVE SYMPTOMS

  • LING-YU LU Department of Pharmacy, Taoyuan Psychiatric Center, Taoyuan, Taiwan.
  • CHUN-CHIA TSAI Department of Pharmacy, Taoyuan Psychiatric Center, Taoyuan, Taiwan

Abstract

Objective: Agomelatine is a new mechanism of antidepressants, which is approved by Taiwan Food and Drug Administration and available in Taiwan.
Agomelatine behaves both as a potent agonist at melatonin MT1 and MT2 receptors and as a neutral antagonist at 5-HT2C receptors. The structures
of agomelatine are similar to melatonin with not only the effects to maintain depression symptoms but also can help patients who have insomnia.
Methods: This is a retrospective study. In a mental hospital in Taoyuan, we analyzed the prescriptions of the outpatients who were prescribed
agomelatine to realize the effects of agomelatine and whether the prescriptions were prescribed appropriately.
Results: Catastrophic illnesses were found to be associated with significantly used multiple hypnotics (χ2 =22.02, p<0.001). When patients’ age
increased by 1 year, multiple hypnotics used increased by 1.013 times (Exp(B)=1.013, p<0.01). Catastrophic illnesses were found to be associated
with significantly used augmentation with other antidepressants (χ2=54.07, p<0.001).
Conclusions: Doctors should be evaluating the benefits and risks when they prescribe a medicine to patients, and they should be written in medical
record. This study is the hope to provide relevant units as a reference for formulating health policies.

Keywords: Agomelatine, Melatonin, Insomnia, Chi-squared test, Logistic regression

References

1. Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ,
Ogawa Y, et al. Comparative efficacy and acceptability of 21
antidepressant drugs for the acute treatment of adults with major
depressive disorder: A systematic review and network meta-analysis.
Lancet 2018;391:1357-66.
2. Li YI, Starr LR, Wray-Lake L. Insomnia mediates the longitudinal
relationship between anxiety and depressive symptoms in a nationally
representative sample of adolescents. Depress Anxiety 2018;35:583-91.
3. Singh SP, Singh V, Kar N. Efficacy of agomelatine in major depressive
disorder: Meta-analysis and appraisal. Int J Neuropsychopharmacol
2012;15:417-28.
4. Guaiana G, Gupta S, Chiodo D, Davies SJ, Haederle K, Koesters M.
Agomelatine versus other antidepressive agents for major depression.
Cochrane Database Syst Rev 2013;12:CD008851.
5. Wu CY, Liang KC. Oral antidepressant-agomelatine. J Taiwan Pharm
2013;116:44-7.
6. Kennedy SH, Heun R, Avedisova A, Ahokas A, Olivier V, Picarel-
Blanchot F, et al. Effect of agomelatine 25-50 mg on functional
outcomes in patients with major depressive disorder. J Affect Disord
2018;238:122-8.
7. Freiesleben SD, Furczyk K. A systematic review of agomelatineinduced
liver injury. J Mol Psychiatry 2015;3:4.
8. Voican CS, Corruble E, Naveau S, Perlemuter G. Antidepressantinduced
liver injury: A review for clinicians. Am J Psychiatry
2014;171:404-15.
9. Holshoe JM. Antidepressants and sleep. In: Reference Module in
Neuroscience and Biobehavioral Psychology. Amsterdam, Netherlands:
Elsevier; 2017.
10. Wichniak A, Wierzbicka A, Walecka M, Jernajczyk W. Effects of
antidepressants on sleep. Curr Psychiatry Rep 2017;19:63.
11. DeSanty KP, Amabile CM. Antidepressant-induced liver injury. Ann
Pharmacother 2007;41:1201-11.
Statistics
43 Views | 56 Downloads
Citations
How to Cite
LU, L.-Y., & TSAI, C.-C. (2021). ANALYSIS OF AGOMELATINE TREATMENT WITH DEPRESSIVE SYMPTOMS. International Journal of Applied Pharmaceutics, 13(1), 63-66. https://doi.org/10.22159/ijap.2021.v13s1.Y0110
Section
Full Proceeding Paper